Business Description
Perspective Therapeutics Inc
NAICS : 339112
SIC : 5047
ISIN : US46489V1044
Description
Perspective Therapeutics Inc is a medical technology and radiopharmaceutical company that is pioneering various treatment applications for cancers throughout the body. The Company has a proprietary technology that utilizes the alpha emitting isotope 212Pb to deliver powerful radiation specifically to cancer cells via specialized targeting peptides.
Financial Strength
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 3.62 | |||||
| Equity-to-Asset | 0.77 | |||||
| Debt-to-Equity | 0.03 | |||||
| Debt-to-EBITDA | -0.07 | |||||
| Piotroski F-Score | 1/9 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year EBITDA Growth Rate | -43.9 | |||||
| 3-Year EPS without NRI Growth Rate | -40.9 | |||||
| 3-Year FCF Growth Rate | -34.8 | |||||
| 3-Year Book Growth Rate | 47.6 |
Momentum Rank
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 79.44 | |||||
| 9-Day RSI | 72.95 | |||||
| 14-Day RSI | 70.2 | |||||
| 6-1 Month Momentum % | 367.77 | |||||
| 12-1 Month Momentum % | 95.38 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 1.07 | |||||
| Quick Ratio | 1.07 | |||||
| Cash Ratio | 0.59 | |||||
| Days Inventory | 122.05 | |||||
| Days Payable | 367.56 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -59.9 | |||||
| Shareholder Yield % | -0.22 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| ROE % | -51.04 | |||||
| ROA % | -45.2 | |||||
| ROIC % | -52.49 | |||||
| ROC (Joel Greenblatt) % | -600.62 | |||||
| ROCE % | -42.61 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PS Ratio | 1600 | |||||
| PB Ratio | 5.93 | |||||
| EV-to-EBIT | -24.47 | |||||
| EV-to-EBITDA | -25.06 | |||||
| EV-to-Forward-Revenue | 53.38 | |||||
| EV-to-FCF | -25.94 | |||||
| Price-to-Median-PS-Value | 160 | |||||
| Earnings Yield (Greenblatt) % | -4.09 | |||||
| FCF Yield % | -4.04 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with AMEX:CATX
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Perspective Therapeutics Inc Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | |||
| EPS (TTM) ($) | -0.172 | ||
| Beta | 2.5 | ||
| Volatility % | 133.96 | ||
| 14-Day RSI | 70.2 | ||
| 14-Day ATR ($) | 0.124433 | ||
| 20-Day SMA ($) | 1.4615 | ||
| 12-1 Month Momentum % | 95.38 | ||
| 52-Week Range ($) | 0.205 - 1.77 | ||
| Shares Outstanding (Mil) | 586.92 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 1 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Perspective Therapeutics Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Perspective Therapeutics Inc Stock Events
| Event | Date | Price($) | ||
|---|---|---|---|---|
| No Event Data | ||||
Perspective Therapeutics Inc Frequently Asked Questions
What is Perspective Therapeutics Inc(CATX)'s stock price today?
The current price of CATX is $1.60. The 52 week high of CATX is $1.77 and 52 week low is $0.21.
When is next earnings date of Perspective Therapeutics Inc(CATX)?
The next earnings date of Perspective Therapeutics Inc(CATX) is 2024-05-06 Est..
Does Perspective Therapeutics Inc(CATX) pay dividends? If so, how much?
Perspective Therapeutics Inc(CATX) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers